Table 3: Effect (hazard ratio, HR) of clinical profiles and treatment on locoregional recurrence, distance recurrence, and death in breast cancer ( ), multivariable analysis (reduced model).

Prognostic factorsLocoregional recurrenceDistant recurrenceDeath
HR (95% CI) valueHR (95% CI) valueHR (95% CI) value

Age (year)
 >45 versus ≤451.07 (0.64–1.78)0.8010.75 (0.50–1.13)0.1640.93 (0.62–1.40)0.722
Pathological tumor size (cm)
 >2 versus ≤21.46 (0.87–2.45)0.1481.26 (0.80–1.97)0.3161.56 (1.02–2.40)0.040
Stage
 3 versus 1 and 21.65 (0.94–2.91)0.0812.44 (1.57–3.80)<0.0012.17 (1.42–3.32)<0.001
Positive axillary lymph nodes
 >3 versus ≤32.43 (1.35–4.37)0.0031.79 (1.10–2.93)0.0202.16 (1.36–3.43)0.001
LVI
 Present versus absent2.01 (1.09–3.71)0.0261.64 (0.96–2.83)0.0732.87 (1.69–4.87)<0.001
Treatment
 Radiotherapy
  Yes versus no0.90 (0.54–1.53)0.7092.40 (1.50–3.84)<0.0011.32 (0.86– 2.03)0.201
 Hormonal therapy
  Yes versus no0.70 (0.44–1.11)0.1280.44 (0.30–0.65)<0.0010.57 (0.40–0.83)0.003
 Chemotherapy
  Yes versus no1.51 (0.45–5.02)0.5021.36 (0.41–4.49)0.6120.27 (0.14–0.52)<0.001

LVI: lymphovascular invasion.